© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Iodixanol came into medical practice during a time when contrast agents started drawing criticism for their safety records and harsh effects on patients. Traditional ionic contrast media frequently caused serious reactions, such as kidney injury, pain, and discomfort. Medical researchers, spurred on by these problems and new regulatory pressure, focused on designing non-ionic, water-soluble, and low-osmolar options. Advances in organic and synthetic chemistry made it possible to create molecules that balanced high iodine delivery—important for imaging visibility—with lower side effects. Nycomed, a Norwegian company, introduced iodixanol under the brand name Visipaque in the 1990s. This kicked off a new standard for contrast agents in radiology, driven by clinical demand for safer products for a wider variety of patients, especially those at risk for kidney issues.
Iodixanol gets sold as a clear, colorless, or slightly yellow solution. Its main use centers on diagnostic imaging—CT scans, angiography, venography, and urography—where visual clarity is critical. Although physicians, nurses, and radiology techs might simply call it “contrast,” it stands apart because it’s iso-osmolar, meaning its osmotic pressure closely matches human blood. That difference plays a big role for patients with diabetes, high blood pressure, or kidney risk, where even small shifts in fluid balance can spell trouble. The product comes in single-use vials with tight specifications on sterility, labeling, and storage. Dosing recommendations reflect both patient body weight and the intended imaging purpose.
Iodixanol’s molecular formula, C35H44I6N6O15, packs six iodine atoms within a dimeric non-ionic configuration, which means the molecule carries no net charge. This structure restricts water movement, lowering its osmolarity and viscosity without skimping on x-ray absorption. Its solubility in water enables the formulation of high-concentration injectable solutions, which makes it easier to use for quick imaging without repeated administrations. Its molecular weight sits at roughly 1550 Da, and at room temperature, the substance remains stable when stored properly. This chemical stability guarantees consistent results throughout shelf life and reduces the risk of unintentional breakdown products.
Every vial of iodixanol carries identification info, batch numbers, expiry dates, concentration (often 270 or 320 mg I/mL), and complete instructions for dilution and injection. Regulations require clear marking for single patient use to block contamination. Storage guidance focuses on keeping the product from light, heat, and freezing, since those forces can mess with both sterility and functional performance. Regulatory filings—the paperwork given to agencies like the FDA or EMA—cite strict impurity limits, biocompatibility data, and patient safety information. The insert supplies practitioners with administration details, contraindications, and what to do if patients have allergies or kidney issues.
Producing iodixanol takes several deliberate steps. Chemists start with a glucose derivative, adding various alkyl groups to achieve non-ionic properties. Reactors get loaded with carefully weighed iodine, which becomes covalently bonded in a way not easily shaken loose. Technicians closely monitor the reaction conditions—temperature, pressure, solvent concentrations—to limit unwanted side products. The result passes through purification steps like filtration and crystallization. Pharmaceutical-grade water mixes in to reach the final concentration, and filling runs take place in clean-room settings to dodge microbes or particulates. Every lot undergoes testing for endotoxins, sterility, and particle content before leaving the facility.
Different patient populations and imaging needs sometimes drive demand for tweaks in formulation. Researchers have experimented with minor adjustments to the side chains that can tune viscosity or solubility. Other labs have looked at chelating agents, surfactants, or buffering salts for greater comfort or stability. These modifications remain limited because the original structure already strikes a solid balance of properties. Still, advances in analytical instrumentation often reveal trace impurities or breakdown products, so manufacturers occasionally revise their synthesis based on new safety data or regulatory standards.
The name iodixanol sticks in scientific circles, but the brand Visipaque has become familiar with hospital staff and doctors worldwide. Chemically-minded professionals might reference alternative titles like iodixanolum (in Latinized international forms) or chemical databases might list the CAS number 92339-11-2. Bulk orders from pharmaceutical wholesalers come labeled by concentration and formulation—each with regulatory codes for tracking.
Hospitals have learned that most major contrast reactions hit within minutes of administration. For this reason, protocols designed around iodixanol stress pre-screening for allergy history, baseline kidney tests, and post-administration observation. Nurses and doctors keep resuscitation drugs on hand for rare but serious reactions. Staff follow strict guidelines for handling sharps, preventing cross-contamination, and logging batch information for every administration. Many facilities now employ real-time digital tracking of contrast agent use, so they can trace any adverse reaction straight back to the source. Global standards from health agencies and medical societies reinforce these practices with regular audits, incident reporting, and continuing education for clinicians.
Iodixanol sees heavy use in radiology and interventional cardiology. Hospitals favor it for patients deemed “high-risk” by kidney or allergy history. Outpatient imaging centers rely on its undramatic side effect profile to speed up day-to-day workflow, limiting delays or overnight observation. It’s important for procedures like coronary angiography, CT angiograms, and dedicated children’s imaging because its lower osmolarity means less stress on delicate tissues. Some oncologists use it in planning and monitoring cancer treatments, particularly in settings that call for frequent imaging. Emergency departments also keep a stock for trauma cases where rapid scanning can’t wait for a long risk assessment.
Over the last decade, research teams have tackled questions about even safer and faster imaging. Some studies test new delivery methods, like using microbubbles with iodixanol or cutting down on total contrast used through advanced software. Others study the biochemistry of kidney injury, comparing iodixanol with up-and-coming agent classes. University centers track effectiveness in low-dose applications and special populations such as premature infants or immunocompromised adults. Pharmaceutical companies monitor post-market reports and collaborate with research hospitals to review real-world outcomes, considering everything from patient satisfaction to long-term renal function.
Toxicology labs have explored how iodixanol interacts with everything from red blood cells to kidney cells. In most healthy adults, the body clears the agent through the urine within hours, leaving little residue. But research has shown that in patients with preexisting renal impairment the risk for contrast-induced nephropathy stays real, even if lower than with old-school agents. Animal models help labs check for genetic or developmental harm, and investigators document every minor reaction. Reports show a low rate of allergic or anaphylactoid responses compared to historic contrast brands. Nevertheless, the rare but serious outcomes keep toxicologists and clinicians hunting for root causes and new prevention measures, like hydration regimens or drug pre-treatment.
Growing imaging demand, an aging population, and pressure for better patient outcomes will keep hospitals and companies focused on improving agents like iodixanol. Regulatory agencies will likely set new rules based on ongoing safety surveillance, and researchers will keep seeking better prediction tools for adverse reactions. It’s likely that future versions will try to push the limits on lower dose requirements, speedier patient recovery, or compatibility with emerging imaging platforms such as artificial intelligence-guided diagnostics. Academic and industry labs will look for ways to incorporate green chemistry principles, shrink environmental waste, and enhance supply chain security to meet global health needs.
Iodixanol turns moments of uncertainty in a hospital into moments of clarity. Its job is to help doctors and nurses take a closer look at what’s going on inside the body. Picture someone worried about a blocked artery or a damaged organ. Traditional X-rays or scans sometimes show only shadows, but with iodixanol, those shadows come to life. It’s a special dye, called a contrast agent, injected before scans like CT or angiography. Organs, blood vessels, and tissues stand out more clearly, and that means doctors catch problems early.
I’ve watched friends and family go through stressful diagnostic tests. The wait, the worry, the questions – it can all feel overwhelming. But a contrast agent like iodixanol speeds up the process, helping radiologists spot injuries or tumors that would otherwise hide. It matters most in emergencies, such as a suspected stroke or blocked artery, where every minute counts. A sharp image means faster answers and, for some, a better shot at recovery. Iodixanol gives medical teams the information they need and gives patients peace of mind that nothing is missed.
Contrast agents have always done a good job making images sharper, but many came with strings attached: allergic reactions or kidney stress, especially for people who are already sick. Iodixanol stands out because of its lower risk profile. It's less likely to trigger allergies and gentler on the kidneys, based on studies in leading journals like The Lancet and Radiology. That’s appealing to doctors treating children, the elderly, or folks with pre-existing kidney issues. Veteran radiologists at top hospitals have shared how moving to iodixanol has lowered complications for their most at-risk patients.
Doctors talk a lot about "osmolality" — how concentrated a contrast agent is compared to the body’s fluids. Lower osmolality agents, like iodixanol, cause less irritation and shift fewer fluids around in the bloodstream. This matters for people with heart failure, diabetes, or compromised immune systems. Real-life cases have shown that switching to iodixanol can help people avoid kidney problems and hospital stays. Patients recover faster because they dodge added stress from the diagnostic process itself.
One challenge stands out: cost. Iodixanol costs more than some older contrast dyes. Hospitals balance budgets, and this becomes a tough decision for administrators. But skipping on patient safety often costs more in the long run — extended hospital stays, complications, extra interventions. Research from major health systems shows that using iodixanol in high-risk populations saves money over time through fewer adverse events. Some clinics have also adopted protocols to identify who benefits most, reserving iodixanol for those with higher risk factors. More supplier competition and smarter purchasing agreements could bring prices down, expanding access to safer care for everyone.
Medical imaging revolutionizes how we catch and treat diseases. Contrast agents like iodixanol amplify those benefits, especially for people who can’t take risks with their health. Learning the science, watching the impact on real people, and considering the economics — it all points to a future where fewer patients fall through the cracks. Doctors, hospitals, and insurers have every reason to keep pushing for the safest, most effective tools in the scanner room. Iodixanol belongs on that list.
Iodixanol often finds its way into hospitals and clinics during imaging procedures, especially CT scans and angiography. As a contrast agent, it lets doctors see blood vessels and organs more clearly. People sitting across from me at the radiology desk sometimes ask if they should brace themselves for problems after the injection. It’s fair for anyone to want honest talk about medication side effects, especially with contrast dyes like iodixanol.
Years of working alongside radiologists have shown me how iodine-based contrast agents can cause mild, short-lived side effects. For iodixanol, the list often starts with warmth or flushing. That odd rush of heat sweeping through the body rarely lasts more than a few seconds. Nausea, headache, and a metallic taste in the mouth may follow. These symptoms sound strange, but they fade fast. In some waiting rooms, you’ll hear patients joke about “taste-testing a penny” after their scan.
Dizziness can catch people off guard. The body registers a sudden shift as the fluid moves through blood vessels. Lingering fatigue sometimes follows, usually mild enough for people to carry on with their day. Itching, hives, or a mild rash do pop up now and then. I watched a few patients rub their arms after an injection, but most skin reactions don’t seem worrisome.
Doctors and nurses stay alert for bigger reactions. Allergic-type symptoms like throat tightness, breathing trouble, swelling around the face or lips, or rapid heartbeat demand immediate care. Real emergencies are rare, especially with modern contrast agents like iodixanol, but ignoring safety never makes sense. Because risk climbs for those with a history of allergies or asthma, doctors often ask a pile of questions about these before imaging starts.
Contrast agents have a reputation for messing with kidney function, especially in older adults or folks with diabetes. I once guided a patient who worried about kidney strain after reading stories online. Labs that check kidney health can bring peace of mind. Extra IV fluids sometimes help flush the agent out faster, and skipping certain medicines before the test gives kidneys a break.
Many folks trust their healthcare teams with big decisions, so sharing plain-spoken facts about risks helps build real relationships. Most people walk away from scans unharmed, but the outliers—those who struggle with more than a mild headache or rash—remind us to stay vigilant. Doctors get thorough training to spot problems early, and most clinics have crash carts and trained staff ready in every imaging suite.
For people who fear allergies, it’s smart to ask for a step-by-step plan before the scan. Some clinics offer “test doses,” or an oral steroid plan, to calm nerves and lower odds of trouble. If previous contrast dyes caused issues, letting the radiology team know ahead of time pays off.
Clear communication between patients and providers cuts confusion and builds trust. Easy-to-read handouts, a nurse who explains risks without jargon, and clinics that listen to people’s past experiences improve safety. As contrast agents go, iodixanol has earned a reputation as a lower-risk option for many, but nothing replaces the watchful eye of experienced staff looking after individual needs.
Walking into a radiology department, you often see patients lined up for various scans—many involving contrast agents like Iodixanol. This substance plays a crucial role in making blood vessels and organs visible during CT scans and angiographies. Its job is straightforward: help radiologists get a clearer view, so nothing gets missed during a diagnosis.
Practitioners usually deliver Iodixanol through an intravenous injection. A nurse or doctor inserts a small needle into a vein, most often in the arm or hand. The amount depends on the scan type, the patient’s size, and the focus area. For someone going in for a heart imaging test, the professional calculates the minimum volume necessary to show detailed structures while reducing the risk of side effects.
Sometimes, a power injector gets used. This device helps control the speed and pressure of the contrast agent as it enters the bloodstream. I remember a situation during clinical practice: the radiologist checked both the patient’s hydration status and kidney function before using an injector. Proper preparation matters. People on certain medications or with kidney issues face higher risks of complications. Hydration and slow, careful injection often make a big difference.
Before giving Iodixanol, medical teams run down a checklist: any previous allergic reactions? Renal function within a safe range? Allergies and kidney function top the list, since iodinated agents can be rough on people with weak kidneys or contrast allergies. In my experience, most people tolerate the process well, but discomfort can occur if the agent leaks outside the vein. Watching the IV site, looking out for swelling or pain, and communicating with the patient lowers the risk of harm.
The medical team often encourages patients to drink fluids before and after the scan. Good hydration helps flush the contrast agent from the body after imaging, reducing the burden on the kidneys. In some places, especially for people with diabetes or kidney disease, staff monitor vital signs for a while after the scan. No one likes surprises, so follow-up matters.
Awareness and preparation give the best shot at avoiding problems. Iodixanol formulas use a non-ionic, iso-osmolar mixture, which research has shown causes fewer adverse reactions compared to older contrast agents. A review published in the American Journal of Roentgenology found that allergic-type reactions and discomfort happen less often with Iodixanol, which is welcome news for patients who have been through tough scans before.
Of course, no agent comes without risk. Lessons from clinical rounds taught me to never overlook the rare but serious reactions—tightness in the chest, hives, or sudden drop in blood pressure can all show up unexpectedly. This underlines the importance of having experienced staff and emergency protocols in imaging suites. Investment in rapid response training saves lives. Hospitals with clear, up-to-date protocols give everyone peace of mind—from patients to radiologists.
Earning trust in the healthcare system means using safe, effective tools while taking time to answer questions and anticipate concerns. Iodixanol, given with care, helps doctors see what the naked eye never could. With the right screening and follow-up, people get the answers they need with fewer worries about the process.
Radiologists and doctors use iodixanol as a contrast dye for CT scans and angiograms. It helps them see blood vessels, organs, and tissues more clearly. For people with healthy kidneys, there’s usually no trouble with this dye. The main concern shows up in patients who already have kidney problems. Their kidneys struggle to clear contrast dyes, so kidney function can get worse after the scan.
Over the years, research has sought out safer alternatives in contrast media. Iodixanol falls into the category of iso-osmolar contrast agents, meaning it has about the same saltiness as blood. Some older agents are high-osmolar, which can suck water out of cells and sometimes lead to complications. Doctors hoped iodixanol would mean fewer problems for people with impaired kidneys.
Contrast-induced nephropathy (CIN) refers to sudden kidney function decline after receiving contrast material. This risk especially worries people with diabetes, prior kidney injury, or older age. Iodixanol seemed like a game changer at first. Early studies hinted at lower risk for kidney harm compared to high-osmolar agents. Yet, wider research—especially randomized trials—shows the difference may not be all that dramatic when compared to modern low-osmolar agents.
A 2021 systematic review and large-scale studies published in leading journals like the New England Journal of Medicine found the rates of CIN after iodixanol and after low-osmolar nonionic dyes were quite similar. Both types become more risky as underlying kidney disease worsens. No magic bullet yet for this particular problem.
Working in a hospital setting, I've seen doctors use iodixanol because it handles well in sensitive patients. Still, the prep makes the real difference. Patients who come in well-hydrated, off certain medications (like metformin or NSAIDs), and have their creatinine monitored tend to dodge the worst complications. Emergency cases, or those who can’t hydrate before imaging, take the biggest risks.
My experience lines up with the literature. Iodixanol offers an extra layer of comfort when patients have moderate chronic kidney disease, but it doesn't wipe away the risk. No dye is entirely risk-free. For some, alternative imaging like MRI (with gadolinium-free agents) or ultrasound might do the trick, sidestepping risk altogether.
Doctors should keep up with good hydration and avoid combining contrast with nephrotoxic drugs. Advanced screening for kidney risk lets teams plan ahead. Hospitals can put harm-reduction protocols in place—proper IV fluids before and after scans, lowering iodine load, and reassessing if a scan is truly needed.
Industry keeps promising safer contrast dyes, but real progress comes from using good judgment. Patients should learn the risks from their care team, ask questions, and help manage conditions like diabetes and high blood pressure. For most people with mild to moderate kidney disease, iodixanol is an option with precautions, not a free pass. Ongoing research still aims for that gold standard of safety—which everyone in medicine hopes will come sooner rather than later.
Iodixanol works as a contrast agent for medical imaging—think CT scans, angiography, or other diagnostic tools. It’s a lifeline for doctors who need clear pictures inside the body. Using it isn’t something to slide into carelessly. Years in healthcare show me one thing: even medications meant to help can cause trouble if you overlook real-world details.
Some folks run into allergic reactions with contrast agents, including Iodixanol. If someone’s had hives, itching, breathing issues, or swelling after previous dyes, this history needs to be shared up front. Even if a person feels healthy, past reactions to shellfish or other iodine-based solutions can tip off the care team. Doctors don’t want to gamble with anaphylaxis—everything starts with a full conversation about allergies.
Contrast dyes challenge kidneys, and Iodixanol is no exception. Any history of kidney problems, diabetes, dehydration, or recent illness means lab tests should happen before the imaging. I learned, after helping care for folks with chronic kidney disease, that even one round of contrast can spark a crisis. Checking creatinine and estimated glomerular filtration rate (eGFR) allows health teams to track risk, plan for hydration, and weigh other imaging options. Strong kidneys filter out Iodixanol quickly; weakened organs struggle, sometimes leading to long-term harm.
Patients taking metformin for Type 2 diabetes face another layer of risk. Metformin can build up in the body if kidneys slow down, leading to lactic acidosis. To steer clear of this, metformin often pauses before and after the scan—never something to skip over. Other medicines, like NSAIDs, diuretics, or drugs that hit the kidneys, deserve a close look too. Each medicine tells a story, so doctors must ask and listen.
Anyone with unstable heart issues, recent heart attack, or severe heart failure should talk with their physician before receiving Iodixanol. Blood pressure swings and irregular rhythms can get worse around contrast agents. Blood disorders like sickle cell anemia or paraproteinemias also appear on the red flag list, since thickened blood or increased viscosity can spark a crisis under strain.
Drinking enough fluids before and after the scan helps protect the kidneys, especially in older adults or those with heart and kidney conditions. Hydration matters even more for people who skip meals for their tests or those living with illnesses that dry them out. Sometimes, hospitals set up IV fluids to top up hydration and flush out the dye faster.
Pregnant people, folks breastfeeding, and children need thoughtful discussion before any imaging with contrast. Risk weighs against benefit, looking at both the mother and the baby’s health. Most cases still go forward if the scan’s essential, but the idea is to avoid unnecessary exposure whenever possible.
No tool in medicine is without risk. Open, honest conversation lays the groundwork—sharing all medications, past reactions, kidney and heart histories. Testing kidney function, planning hydration, and adjusting medicines beforehand gives the best shot at a safe, smooth scan. Medicine works best with trust and teamwork. Safety rises when everyone brings their story to the table.
| Names | |
| Preferred IUPAC name | 5-[N-(2,3-dihydroxypropyl)acetamido]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide |
| Other names |
Visipaque Iodixanolum Iodixanol 320 GEH 132 320 GE Healthcare 132 |
| Pronunciation | /ˌaɪ.əˈdɪk.sə.nɒl/ |
| Identifiers | |
| CAS Number | 92339-11-2 |
| 3D model (JSmol) | `3D model (JSmol) string for Iodixanol`: `C1=CC(=CC=C1COC(CNC(=O)COC2=CC(=CC(=C2)O)I)O)I.CNC(=O)COC3=CC(=C(C(=C3I)O)OCC(=O)NC)I` |
| Beilstein Reference | 60743 |
| ChEBI | CHEBI:31943 |
| ChEMBL | CHEMBL1200703 |
| ChemSpider | 27701 |
| DrugBank | DB01252 |
| ECHA InfoCard | 100.081.390 |
| EC Number | 6851-28-3 |
| Gmelin Reference | 877519 |
| KEGG | C13424 |
| MeSH | D000072863 |
| PubChem CID | 441240 |
| RTECS number | YI4079Q12M |
| UNII | XN1O07T4TN |
| UN number | UN3332 |
| CompTox Dashboard (EPA) | 3W97749F2A |
| Properties | |
| Chemical formula | C35H44I6N6O15 |
| Molar mass | 1550.198 g/mol |
| Appearance | White powder |
| Odor | Odorless |
| Density | 1.28 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -2.6 |
| Vapor pressure | < 0.01 mmHg (20 °C) |
| Acidity (pKa) | 8.8 |
| Basicity (pKb) | 12.6 |
| Magnetic susceptibility (χ) | -8.0e-6 cm³/mol |
| Refractive index (nD) | 1.479 |
| Viscosity | 11.3 mPa·s |
| Dipole moment | 0.98 D |
| Pharmacology | |
| ATC code | V08AB09 |
| Hazards | |
| Main hazards | Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | P264, P280, P301+P312, P305+P351+P338, P337+P313 |
| Lethal dose or concentration | LD₅₀ (rat, intravenous): >10 g/kg |
| LD50 (median dose) | LD50 (median dose): > 15,000 mg/kg (rat, intravenous) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 320 mgI/mL |
| Related compounds | |
| Related compounds |
Iohexol Iopamidol Ioversol Iomeprol Iopromide Iodinated contrast media |
